Loading...
Relapsed acute lymphoblastic leukemia
Sidhu, J. Gogoi, M. P. Krishnan, Shekhar Saha, Vaskar
Sidhu, J.
Gogoi, M. P.
Krishnan, Shekhar
Saha, Vaskar
Citations
Altmetric:
Abstract
Outcomes for children with acute lymphoblastic leukemia (ALL) have improved worldwide to >85%. For those who relapse, outcomes have remained static at ~50% making relapsed acute lymphoblastic leukemia one of the leading causes of death in childhood cancers. Those relapsing within 18 mo in the bone marrow have a particularly dismal outcome. The mainstay of treatment is chemotherapy, local radiotherapy with or without hematopoietic stem cell transplantation (HSCT). Improved biological understanding of mechanisms of relapse and drug resistance, use of innovative strategies to identify the most effective and least toxic treatment regimens and global partnerships are needed to improve outcomes in these patients. Over the last decade, new therapeutic options and strategies have been developed for relapsed ALL including immunotherapies and cellular therapies. It is imperative to understand how and when to use these newer approaches in relapsed ALL. Increasingly, integrated precision oncology strategies are being used to individualize treatment of patients with relapsed ALL, especially in patients with poor response disease.
Description
Date
2023
Publisher
Collections
Files
Keywords
Type
Article
Citation
Sidhu J, Gogoi MP, Krishnan S, Saha V. Relapsed Acute Lymphoblastic Leukemia. Indian journal of pediatrics. 2023 Jun 21. PubMed PMID: 37341952. Epub 2023/06/21. eng.